ALK-Abelló A/S
ALK-Abelló A/S
Your view on AKBLF
Overview
What the company does, where it operates, and who runs it.
About ALK-Abelló A/S
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Peter Halling
- Headquarters
- Boge Alle 6-8, Horsholm, DK
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Peter Halling
- Headquarters
- Boge Alle 6-8, Horsholm, DK
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for ALK-Abelló A/S, and the rating behind it. AKBLF last traded at $36.10, 41.9× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for ALK-Abelló A/S. Starting points for ALK-Abelló A/S: P/E 41.9, EPS $0.91, beta 0.58 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for ALK-Abelló A/S. ALK-Abelló A/S does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for ALK-Abelló A/S. Trailing twelve-month EPS for ALK-Abelló A/S stands at $0.91. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for ALK-Abelló A/S. ALK-Abelló A/S has reported as a listed company since 2009. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
ALK-Abelló A/S valued side by side against its closest peers. ALK-Abelló A/S is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold ALK-Abelló A/S, and how their positions are changing. At a $7.27B market value, institutional positions materially move ALK-Abelló A/S's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by ALK-Abelló A/S executives and directors. Shares of ALK-Abelló A/S have traded between $19.90 and $36.14 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming ALK-Abelló A/S. ALK-Abelló A/S is a $7.27B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming ALK-Abelló A/S. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for ALK-Abelló A/S. Coverage tracks ALK-Abelló A/S within Biotechnology (Healthcare). Press releases and market coverage, newest first.